This week in photos: Trump with Pope, St Nicholas relics in Moscow and Zuckerberg's degreeSociety & Culture May 26, 17:45
Bolshoi Theater vows to put on at least 10 new shows next seasonSociety & Culture May 26, 17:34
First out of four IS members detained in Moscow arrested for 2 monthsSociety & Culture May 26, 17:17
Putin says attackers, masterminds of terror attack in Egypt must not go unpunishedRussian Politics & Diplomacy May 26, 17:13
Russian oil and gas companies may use Ka-62 helicopter for Arctic projectsBusiness & Economy May 26, 17:05
Russia may increase spending on military bases abroadMilitary & Defense May 26, 16:45
Lavrov praises Eurasian integration projectsBusiness & Economy May 26, 16:40
Estonian Foreign Ministry confirms plans to expel two Russian diplomatsWorld May 26, 16:30
Russia stands for diplomatic settlement of North Korean issue — presidential aideRussian Politics & Diplomacy May 26, 16:25
LUGANO, Switzerland, January 19, 2017/PRNewswire/ -- Biosimilars create opportunities for sustainable cancer care, says ESMO in a position paper published in ESMO Open. The document outlines approval standards for biosimilars, how to safely introduce them into the clinic and potential benefits for patients and healthcare systems.
"Biosimilars are must-have weaponry in financially sustaining healthcare systems on a global scale and significantly improving outcomes for an increasing number of patients throughout Europe and the rest of the world," said ESMO President Professor Fortunato Ciardiello.
Unlike generics, which are chemically synthesised and are identical copies of the original drug, biosimilars require clinical studies to ensure that the manufacturing process is sound and does not differ from that of the originator biologic.
In Europe, price reductions for biosimilars are expected to range from 20-40%: potential savings of €50-100 billion by 2020 have been forecast. The majority of monoclonal antibodies are set to come off patent by 2020, which will open the door for biosimilars and could dramatically change the oncology landscape.
Prof Josep Tabernero, ESMO Cancer Medicines Working Group Chair, said: "The paper highlights a number of areas that should be carefully considered by all stakeholders including prescribers, pharmacists, nurses, patients, reimbursement bodies, manufacturers. It also outlines directions that will need to be collectively followed to guarantee the highest safety and efficacy standards of these medicines and ensure that all patients, irrespective of geographical borders, can access the very best evidence based treatments."
Full story: http://bit.ly/2iAfGMt
ESMO is the leading professional organisation for medical oncology, comprising more than 15,000 oncology professionals from over 130 countries, We are the society of reference for oncology education and information, committed to supporting our members to develop and advance in a fast-evolving professional environment.
ESMO Press Office
Source: European Society for Medical Oncology (ESMO)